Who
Jacqualyn A. Fouse
Director
Company insider
Files Form 4 as: Chief Executive Officer, Agios Pharmaceuticals; Director, Madrigal Pharmaceuticals; Director, Incyte; Director, Dick's Sporting Goods; Chief Financial Officer, Celgene Corp /de/; Director, Perrigo Company; Director, Perrigo Co; Chief Financial Officer, Bunge.
In numbers
- Trades disclosed
- 241
- Buys
- 7
- Sells
- 5
- Bought
- $1.7M
- Sold
- $1.1M
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 23 Jul 2007
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —366 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —203 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
News
Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Jacqualyn A. Fouse; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.